Hemagen completes exchange offer for $4.05 million in 8% convertibles

By Devika Patel

Knoxville, Tenn., Oct. 1 - Hemagen Diagnostics Inc. said it exchanged all $4.05 million of its 8% senior subordinated secured convertible notes due 2009 for an equal principal amount of 8% senior subordinated secured convertible notes due 2014.

As previously reported, the new notes will be convertible into common stock at $0.35 per share after Sept. 30, will mature on Sept. 30, 2014 and will pay an 8% annual interest on a quarterly basis.

Hemagen may prepay the notes anytime after Sept. 30, 2010.

The modified notes will have a similar security interest as the previous notes and, therefore, will be subordinated to a $3 million credit facility and any real estate financing the company may incur when buying its corporate facility.

Hemagen, a Columbia, Md.-based biotechnology company, was the exchange agent for the offer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.